title: OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.
authors.forename: D L
authors.initials: DL
authors.lastname: White
authors.forename: V A
authors.initials: VA
authors.lastname: Saunders
authors.forename: P
authors.initials: P
authors.lastname: Dang
authors.forename: J
authors.initials: J
authors.lastname: Engler
authors.forename: T P
authors.initials: TP
authors.lastname: Hughes
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D050811:Octamer Transcription Factor-1 / Q000235:genetics* / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D050811:Octamer Transcription Factor-1; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate